Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawmakers "Don't Care" About Safety Concerns With Rx Imports - GSK

This article was originally published in The Pink Sheet Daily

Executive Summary

Congress' push to pass legislation that would legalize drug importation shows that it has placed political matters ahead of safety concerns, GlaxoSmithKline said Sept. 14 at the Bear Stearns health care conference in New York.

You may also be interested in...



Reimportation Law Unlikely This Year Despite Democratic Pressure

Senate Majority Leader Frist says he does not expect to fit Rx import language into the schedule during the session’s remaining days. The Senate Health Committee has no plans to markup a bill.

Once Safety Issues Are Addressed, Rx Importation "Makes Sense," President Bush Says

Outstanding safety concerns are the sole reason for not yet allowing reimportation from Canada, Bush says during Q&A session with voters. By making drug imports a question of resources, he opens the door to approving some version of the practice.

GSK Sales Reps Will Speak Out Against Rx Importation In Grassroots Effort

Sales reps are encouraged to advance GSK's agenda on importation directly to patients through community meetings. The company expressed optimism that the program could reach millions of U.S. citizens before the 2004 elections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel